Search

Displaying results 2231 - 2240 of 7502 in total
  1. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    [A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma

  2. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    be good candidates for using the agent owing to its physical effects on the gut. … results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  3. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    growth hormone caused by growth hormone deficiency, marking Canada as the first country to approve this drug. … It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and

  4. Drug

    Aminolevulinic acid

    go.drugbank.com/drugs/DB00855
    ApprovedInvestigational

    A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]

  5. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. … Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  6. Drug

    Balsam of Peru

    go.drugbank.com/drugs/DB11482
    ApprovedNutraceuticalVet approved

    [L2879] By Health Canada, the balsam of Peru is approved by the use of over-the-counter combination products and it is currently approved in veterinary products. … It is constituted by a mixture of substances from which the major components are benzyl cinnamate and [DB00676].

  7. Drug

    Bortezomib

    go.drugbank.com/drugs/DB00188
    ApprovedInvestigational

    [A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. … apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.

    Synonyms: N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
  8. Drug

    Oxymorphone

    go.drugbank.com/drugs/DB01192
    ApprovedVet approved

    On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation. … It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092).

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Cupric oxide

    go.drugbank.com/drugs/DB11134
    Approved

    Cupric oxide poses potential health and environmental concern due to toxic and mutagenic particles generating reactive oxygen species [A32656].

  10. Drug

    Pheniprazine

    go.drugbank.com/drugs/DB09250
    ApprovedWithdrawn

    Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome